NCT07525635 Aspirin Dosing in Pregnancy
| NCT ID | NCT07525635 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | NYU Langone Health |
| Condition | Preeclampsia Possible |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-04-27 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2026-04-27 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Eligibility Criteria
Inclusion Criteria: * Pregnant people prior to 17 weeks * Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates * Age 18-50 years * Singleton viable gestation * Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors. Exclusion Criteria: * Undergoing glucose challenge test (GCT) at time of blood draw * Allergy or intolerance to aspirin * Antithrombotic or antiplatelet therapy * Anemia (hemoglobin \<10 g/dl) or thrombocytopenia (platelet count \<100,000), or thrombocytosis (platelet count \>600,000) * Known hemorrhagic diathesis * Planned delivery outside of NYU
Contact & Investigator
Christina A. Penfield, MD, MPH
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT07525635 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Preeclampsia Possible. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07525635 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07525635 currently recruiting?
Yes, NCT07525635 is actively recruiting participants. Contact the research team at Christina.Penfield@nyulangone.org for enrollment information.
Where is the NCT07525635 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07525635 clinical trial?
NCT07525635 is sponsored by NYU Langone Health. The principal investigator is Christina A. Penfield, MD, MPH at NYU Langone Health. The trial plans to enroll 30 participants.